Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 16779736.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Humanized monoclonal antibodies to tumor necrosis factor- alpha are valuable for the treatment of rheumatologic conditions, but they have been associated with the development of serious infections. We report the first 2 cases of leprosy developing after treatment with infliximab. After discontinuation of infliximab, both patients developed type 1 ("reversal") leprosy reactions.
Medical subject headings
- Antibodies, Monoclonal
- Antirheumatic Agents
- Arthritis
- Leprosy, Borderline